March 4th- TP53-mutated CLL in the very elderly: choosing the least harmful effective sequence

March 2nd- Dr. Rahul Banerjee- Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data

February 26th- Extramedullary Disease in Multiple Myeloma: Biology, Treatment, and the Road Ahead

February 24th- Defining Cure in Multiple Myeloma: A Community Consensus Moment

February 23rd- Prof. Roni Shouval- Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

February 22nd- Beyond the webinar: Chronic GVHD in 2026: From Frustration to Structured Progress

February 16th- Dr. Marie Robin- Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability

February 15th- CML in 2026: From Disease Control to Functional Cure

February 9th- Dr. Hira Mian- Redefining the Treatment Landscape of Multiple Myeloma – Key Messages from the 2026 ASCO–Ontario Health Living Guideline

February 4th- A New Step Forward in Chronic GVHD Care